GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Beta

Bioasis Technologies (Bioasis Technologies) Beta : 0.81 (As of Jun. 09, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioasis Technologies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-09), Bioasis Technologies's Beta is 0.81.


Bioasis Technologies Beta Historical Data

The historical data trend for Bioasis Technologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Beta Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 -0.38 -0.83 0.35 0.39

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.39 0.65 0.60 0.54

Competitive Comparison of Bioasis Technologies's Beta

For the Biotechnology subindustry, Bioasis Technologies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Beta distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Beta falls into.



Bioasis Technologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Bioasis Technologies  (OTCPK:BIOAF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Bioasis Technologies Beta Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (Bioasis Technologies) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (Bioasis Technologies) Headlines

From GuruFocus

Bioasis Provides Update on Business Operations

By GlobeNewswire GlobeNewswire 03-23-2023

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

By GuruFocusNews GuruFocusNews 06-26-2022

Bioasis Technologies Inc. Announces Stock Option Grants

By GlobeNewswire GlobeNewswire 08-08-2022

Bioasis Technologies Inc. Announces Shareholder Webinar

By Value_Insider Value_Insider 12-15-2022

Bioasis Announces AGM Results and Provides Update on Financial Position

By GlobeNewswire GlobeNewswire 02-03-2023

Bioasis Provides Corporate Update and Announces Suspension of Operations

By GlobeNewswire GlobeNewswire 06-20-2023

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

By GuruFocusNews GuruFocusNews 07-06-2022